CoChat

Improved PIEZO1 agonism through 4‐benzoic acid modification of Yoda1

Open access
Parsonage, Gregory, Cuthbertson, Kevin, Endesh, Naima, Murciano, Nicoletta, Hyman, Adam J., Revill, Charlotte H., Povstyan, Oleksandr V., Chuntharpursat‐Bon, Eulashini, Debant, Marjolaine, Ludlow, Melanie J., Futers, Timothy Simon, Lichtenstein, Laeticia, Kinsella, Jacob A., Bartoli, Fiona, Rotordam, Maria Giustina, Becker, Nadine, Brüggemann, Andrea, Foster, Richard, Beech, David J. · 2023 · British Journal of Pharmacology
Cited by 62

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Abstract

Background and Purpose: The protein PIEZO1 forms mechanically activated, calcium‐permeable, non‐selective cation channels in numerous cell types from several species. Options for pharmacological modulation are limited and so we modified a small‐molecule agonist at PIEZO1 channels (Yoda1) to increase the ability to modulate these channels. Experimental Approach: Medicinal chemistry generated Yoda1 analogues that were tested in intracellular calcium and patch‐clamp assays on cultured cells exogenously expressing human or mouse PIEZO1 or mouse PIEZO2. Physicochemical assays and wire myography assays on veins from mice with genetic disruption of PIEZO1. Key Results: A Yoda1 analogue (KC159) containing 4‐benzoic acid instead of the pyrazine of Yoda1 and its potassium salt (KC289) have equivalent or improved reliability, efficacy and potency, compared with Yoda1 in functional assays. Tested against overexpressed mouse PIEZO1 in calcium assays, the order of potency (as EC 50 values, nM) was KC289, 150 > KC159 280 > Yoda1, 600). These compounds were selective for PIEZO1 over other membrane proteins, and the physicochemical properties were more suited to physiological conditions than those of Yoda1. The vasorelaxant effects were consistent with PIEZO1 agonism. In contrast, substitution with 2‐benzoic acid failed to generate a modulator. Conclusion and Implications: 4‐Benzoic acid modification of Yoda1 improves PIEZO1 agonist activity at PIEZO1 channels. We suggest naming this new modulator Yoda2. It should be a useful tool compound in physiological assays and facilitate efforts to identify a binding site. Such compounds may have therapeutic potential, for example, in diseases linked genetically to PIEZO1 such as lymphatic dysplasia.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/bph.15996

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 16 references

Cited by

See all 62

Metadata

Authors
Parsonage, G., Cuthbertson, K., Endesh, N., Murciano, N., Hyman, A. J., Revill, C. H., Povstyan, O. V., Chuntharpursat‐Bon, E., Debant, M., Ludlow, M. J., Futers, T. S., Lichtenstein, L., Kinsella, J. A., Bartoli, F., Rotordam, M. G., Becker, N., Brüggemann, A., Foster, R., & Beech, D. J.
Venue
British Journal of Pharmacology
Publisher
Wiley
Published
2023-01-31
Volume
180
Issue
16
Pages
2039-2063
ISSN
  • 0007-1188 (ISSN-L)
  • 1476-5381
OpenAlex
W4310588821
Cited by
62
References
16
FWCI
5.80
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Improved PIEZO1 agonism through 4‐benzoic acid modification of Yoda1. https://app.cochat.ai/papers/10.1111/bph.15996
The paper
Parsonage, G., Cuthbertson, K., Endesh, N., Murciano, N., Hyman, A. J., Revill, C. H., Povstyan, O. V., Chuntharpursat‐Bon, E., Debant, M., Ludlow, M. J., Futers, T. S., Lichtenstein, L., Kinsella, J. A., Bartoli, F., Rotordam, M. G., Becker, N., Brüggemann, A., Foster, R., & Beech, D. J. (2023). Improved PIEZO1 agonism through 4‐benzoic acid modification of Yoda1. British Journal of Pharmacology. https://doi.org/10.1111/bph.15996

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.